Peter Homberg – gunnercooke

Partner – Life Sciences, Corporate, M&A & Intellectual Property

Peter Homberg specializes in life sciences, IP and corporate law, and M&A transactions. He particularly advises companies in the pharmaceutical, diagnostics, medical device and biotechnology sectors on research and development contracts, collaboration agreements, cross-border IP licensing and IP strategies. He also has extensive experience in advising on compliance issues and advises companies extensively in the field of medical cannabis. He is a frequent speaker at seminars and conferences and is the author of numerous articles and other publications on corporate or IP law in the areas of life sciences and medical cannabis. In addition, he has extensive transaction experience in Southeast Asia.

His clients include start-ups and medium-sized companies, as well as listed companies, nationally and internationally operating corporate groups, financial investors and strategic investors.

Experience

  • DEMECAN GmbH: Preparation of a legal opinion on the compatibility of the legalization of cannabis for recreational purposes in Germany with international and European law. Identification of possible solutions to overcome obstacles under international and European law.
  • Canopy Growth Corp.: Advising a subsidiary of one of the leading Canadian medical cannabis suppliers on the acquisition of the German inhaler manufacturer Storz & Bickel GmbH & Co. KG for €135 million.
  • Proteona Pte. Ltd.: Advising biotech company on an exclusive worldwide licensing agreement with the National University of Singapore (NUS).
  • Canadian medical cannabis supplier: Advising on the conclusion of a joint venture agreement with a German pharmaceutical wholesaler.
  • Scil Technology GmbH: Advising regarding the out-licensing of certain intellectual property for the regenerative treatment of inter alia Osteoarthritis to Sanofi.
  • Scil Technology GmbH: Advising regarding the sale of its service and production division to Nanohale AG.
  • German biotechnology company: Advising regarding the sale of a certain IP-portfolio for the treatment of cardiac insufficiency.
  • German mid-size pharmaceutical company: Advising regarding the licensing and distribution of a certain API for the treatment of interstitial cystitis to a multinational US-based pharmaceutical company.
  • US-based pharmaceutical enterprise: Advising regarding the due diligence in connection with a certain technology portfolio for the manufacturing of vaccines prior to the in-licensing of the technology.
  • Swiss-based biotechnology company: Advising regarding cooperation with a French multinational pharmaceutical enterprise.
  • Priaxon AG: Advising regarding the out-licensing of a certain technology to Boehringer Ingelheim.
  • German-Singaporean biotech company: Advising regarding the in-licensing of a certain diagnostic technology from the National University of Singapore.
  • French venture capital fund: Advising regarding the acquisition of shares in a German-based biotechnology company.
  • German medium-size pharmaceutical company: Advising regarding the restructuring of its distribution channels in Portugal and in other European countries.
  • Various clients in the life sciences sector: Advising in all types of transactions, including technology transfer agreements, R&D agreements, M&A transactions, private equity transactions, arbitration proceedings and litigations.

Career History

  • 2012 -2024: Partner, Dentons (formerly Salans)
  • 2010-2012: Partner, (Head of German Life Sciences Practice) Raupach & Wollert-Elmendorff, Frankfurt
  • 2001-2009: Partner, Jones Day (Head of German and European Life Sciences Practice and Intellectual Property Practice), Frankfurt
  • 1996-2001: Deputy Head of Legal Department, Roche Diagnostics GmbH, Mannheim
  • 1994-1996: Head of the investment projects department, Debis Marketing Services
  • 1990-1994: Head of Singapore office, Thümmel Schütze & Partner, Singapore
  • 1989-1990: In-house Counsel, C. Wuppesahl Insurance Brokers

Memberships

  • Member, Licensing Executive Society (LES)
  • Member, German Association for Intellectual Property and Copyright (GRUR)
  • Member, German Institution for Arbitration (DIS)
  • Member, Pharma-Lizenz-Club Deutschland e. V.
  • Member, Branchenverband Cannabiswirtschaft e. V. (BvCW)

Education

  • Georg-August-University, Göttingen, Germany

Publications

  • Co-author, “The permissibility of trading cannabis seeds,” Legal Industry Reviews Germany Vol. 5, September 2024
  • “Die Umsetzungspläne zur zweiten Säule der Cannabislegalisierung – ein Ausblick,” krautinvest, May 2024
  • “Online Platforms for Medical Cannabis Treatment and Legal Pitfalls,” Legal Industry Reviews Germany Vol. 4, April 2024
  • “Bundesrat macht den Weg für das Gesetz zum kontrollierten Umgang mit Cannabis frei,” Dentons Client Alert, March 2024
  • “Bundesrat gibt eine erste Stellungnahme zum geplanten Cannabisgesetz (“CanG”) ab,” Dentons Client Alert, October 2023
  • “Draft Bill German Cannabis Law—Consequences for Medical Cannabis,” Legal Industry Reviews Germany Vol. 2, September 2023
  • FOCUS online expert series on cannabis law with regular contributions, since April 2023
  • “CBD Oils: Food or Pharmaceutical?,” Legal Industry Reviews Germany Vol. 3, December 2023
  • “Current Developments in the German Legalization Process,” Cannabis Law Journal, November 2023
  • “Legalization in Germany: Official Draft Draft Law Published,” Cannabis Law Journal, September 2023
  • “Draft Bill German Cannabis Law—Consequences for Medical Cannabis,” Legal Industry Reviews Germany Vol. 2, September 2023
  • “Recent developments in the German legalization process of recreational cannabis,” Legal Industry Reviews Germany Vol. 1, May 2023
  • “Marketability of CBD products in Germany and the European Union,” Cannabis Law Journal, December 2022
  • “Grundlegende Änderungen in der zukünftigen Verschreibungspraxis von Medizinalcannabis,” krautinvest, December 2022
  • “Key Proposals Paper: New Details on Planned Cannabis Legalization in Germany,” Cannabis Law Journal, November 2022
  • “Geplante Cannabis-Legalisierung – Zwischen Wunschdenken und Rechtsrealität,” LTO, September 2022
  • “The Fate of the German Medicinal Cannabis Industry Post-Legalization,” Cannabis Law Journal, August 2022
  • “Online-Handel von Cannabis: Der Vertriebsweg der Zukunft?,” krautinvest, July 2022
  • “Legalization in Europe?—Candidates for the legalization of recreational cannabis in the near future,” Cannabis Law Journal, May 2022
  • “Warum die Legalisierung von Freizeitcannabis völkerrechtlich bedenklich ist,” krautinvest, April 2022
  • “The legalization of recreational cannabis in conflict to the UN Single Convention on Narcotic Drugs 1961,” Cannabis Law Report, December 2021
  • “Harmonisierung des Rechtsrahmens für medizinisches Cannabis auf EU-Ebene,” krautinvest, November 2021
    Co-author, “Die Pflicht zur Deckungsvorsorge nach § 94 AMG für bestrahlte Cannabisblüten,” Pharma Recht 09/2021
  • “Künstliche Intelligenz unter der EU-Medizinprodukteverordnung,” Science4Life, 2021
  • “Neue Entwicklungen im deutschen Markt für medizinisches Cannabis und Cannabidiol (CBD) 2021 – ein Überblick,” Going Public, Biotechnology, 2021
  • Column about German and European regulation of medical cannabis, Cannabis Law Report, since 2020

Presentations

Peter regularly holds lectures at seminars and conferences. He also holds a monthly deep-dive webinar on current topics of medical cannabis law and the German and international medical cannabis market.

  • “Model Projects – Are They the Path to Pan-European Legalization?,” Panel Discussion, CB Expo 2024 in Dortmund, September 2024
  • “All over the place: The journey to GMP compliance,” Panel Discussion, CB Expo 2024 in Dortmund, September 2024
  • “Medical Cannabis in Germany”, ICBC Science & Technology 2024 in Bled, Slovenia, September 2024
  • “Werben & Verkaufen—Aktuelle Themen für den Handel rund um legale Hanf-Cannabisprodukte,” Panel Discussion, Mary Jane in Berlin, June 2024
  • “Development of Laws and Regs in the EU and UK with regard to Cannabis,” Panel Discussion, LegalTechTalk 2024 in London, June 2024
  • “The European Cannabis Industry—Challenges, Pitfalls and Outlook,” Keynote Speech, International Cannabis Business Conference, April 2024„Bio-Tech and Drug Development,” Talman Global Investment Forum, April 2024
  • “German Legislation on Cannabis,” National Council in Slovenia, February 2024
  • “Cannabis Legalization in Germany,” Keynote Speech, International Cannabis Business Conference, Slovenia, September 2023
  • „Five Years of Cannabis-As-Medicine-Act. The German Way“, Keynote Speech, International Cannabis Business Conference, Berlin, Juli 2023
  • “Cannabis Legalization in Germany,” Keynote Speech, International Cannabis Business Conference, Berlin, June 2023
  • “Cannabis Legalization in Germany,” Keynote Speech, International Cannabis Business Conference, Slovenia, September 2023
  • “Cannabis Legalization in Germany,” Keynote Speech, International Cannabis Business Conference, Berlin, June 2023
  • “Five Years of Cannabis-As-Medicine-Act. The German Way,” Keynote Speech, International Cannabis Business Conference, Berlin, July 2022
  • “Cannabis Legalization in Germany”, Keynote Speech, Keynote Speech, International Cannabis Business Conference, June 2022
  • “The German Way to Medical and Recreational Cannabis,” Keynote speech, Cannabis Business Europe Conference, Berlin, June 2022
  • “Developments of the German Cannabis Market,” Keynote speech, European Medical Cannabis Conference, September 2021
  • “Medical Cannabis from German Cultivation,” Keynote speech, International Cannabis Business Conference, August 2021

Publications with relation to cannabis matters

Social Media

Peter Homberg – gunnercooke

Address & Contacts

Address

Kurfürstendamm 15 10719 Berlin

GPS

52.5043097, 13.3324005

Telephone

+49 (0) 30 220 131 000

Email

[email protected]

Web